Discover the latest advancements in strain development for optimizing the production of complex recombinant proteins using Escherichia coli.
E. coli has gained a reputation for being a fast and economical option for expressing complex molecules but not all proteins are the same.
As an increasing number of promising novel drug targets are discovered, many difficult-to-express and harder-to-produce compounds are reaching and subsequently failing in the development phase, demanding a new generation of unique microbial manufacturing solutions.
In this webinar, the expert speaker will discuss how innovative microbial technologies will allow for improved production of recombinant proteins, including therapeutic proteins for new medicinal products.
More specifically, the speaker will present Vectron Biosolutions’ recent research using novel, in-house technology platforms for expression vector design and secretion in E. coli. These technologies allow for the cost-efficient production of biologically active proteins, which are then transported out of the cell for simplified downstream processing.
The success of any microbial program with commercial aspirations must be built on an expert strain development strategy with current good manufacturing practices (CGMP) in mind. The speaker will briefly focus on strain development and how biomanufacturing can help create a one-stop shop for next-generation drug developers looking to hit their next milestone.
Register for this webinar today to explore the advancements in strain development for the efficient production of recombinant proteins using Escherichia coli.
Speaker
Dr. Trond Erik Vee Aune, CEO, Vectron Biosolutions AS
Dr. Trond Erik Vee Aune is an expert on bacterial gene expression. As part of his PhD on high-level recombinant protein production in bacteria, Aune co-developed a set of expression vectors for controlled gene expression in bacteria and worked on directed enzyme evolution, structure and function of transcription regulators, synthetic biology, research into novel transformation methods and controlled gene expression. As an Inventor, Founder and CEO of Vectron, Aune has become an experienced life science industry professional involved in licensing, IP management, M&As and sales and marketing.
Who Should Attend?
This webinar will appeal to anyone interested in advances in recombinant protein production and in particular E. coli:
- Strain development professionals
- Gene Expression/Process Development/Analytical Development Scientists
- Drug developers
- Business development professionals from biotech companies
- Managers and Directors from biotech companies
What You Will Learn
Attendees will learn about:
- E. coli’s position as the most popular host for recombinant protein production and its industrial future
- Recent advances in the engineering of E. coli for improved recombinant protein production
- How VB Expression™ and VB Secretion™ are expected to reduce the cost-of-goods of using E. coli to produce proteins and peptides
- How strain development and CGMP biomanufacturing excellence result in an attractive partnership for customers
Xtalks Partner
Cytovance® Biologics
Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation, such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well-integrated development services supporting the entire product lifecycle, including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.
Related Webinars
Downstream Process Development of a Complicated Fusion Protein
Regulatory Strategies for Gene Therapy Product Development
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account